Marian Jarlenski1, Elizabeth E Krans2, Qingwen Chen3, Scott D Rothenberger4, Abigail Cartus5, Kara Zivin6, Lisa M Bodnar7. 1. Dept of Health Policy and Management, University of Pittsburgh, 130 DeSoto Street Pittsburgh, PA 15261, USA. Electronic address: marian.jarlenski@pitt.edu. 2. Magee-Womens Research Institute and Dept of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, 3380 Boulevard of the Allies, Pittsburgh, PA 15213, USA. 3. Dept of Health Policy and Management, University of Pittsburgh, 130 DeSoto Street Pittsburgh, PA 15261, USA. 4. Dept of General Internal Medicine, University of Pittsburgh, 200 Meyran Ave, Suite 300, Pittsburgh, PA 15213, USA. 5. Dept of Epidemiology, University of Pittsburgh, 130 DeSoto Street, Pittsburgh, PA 15261 USA. 6. Dept of Psychiatry, University of Michigan, 2800 Plymouth Road, Building 16, Room 228W, Ann Arbor, MI 48109, USA. 7. Magee-Womens Research Institute and Dept of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, 3380 Boulevard of the Allies, Pittsburgh, PA 15213, USA; Dept of Epidemiology, University of Pittsburgh, 130 DeSoto Street, Pittsburgh, PA 15261 USA.
Abstract
BACKGROUND: The contribution of substance use disorders to the burden of severe maternal morbidity in the United States is poorly understood. The objective was to estimate the independent association between substance use disorders during pregnancy and risk of severe maternal morbidity. METHODS: Retrospective analysis of a weighted 53.4 million delivery hospitalizations from 2003 to 2016 among females aged>18 in the National Inpatient Sample. We constructed measures of substance use disorders using diagnostic codes for cannabis, opioids, and stimulants (amphetamines or cocaine) abuse or dependence during pregnancy. The outcome was the presence of any of the 21 CDC indicators of severe maternal morbidity. Using weighted multivariable logistic regression, we estimated the association between substance use disorders and adjusted risk of severe maternal morbidity. Because older age at delivery is predictive of severe maternal morbidity, we tested for effect modification between substance use and maternal age by age group (18-34 y vs >34 y). RESULTS: Pregnant women with an opioid use disorder had an increased risk of severe maternal morbidity compared with women without an opioid use disorder (18-34 years: aOR: 1.51; 95 % CI: 1.41,1.61, >34 years: aOR: 1.17; 95 % CI: 1.00,1.38). Compared with their counterparts without stimulant use disorders, pregnant women with a simulant use disorder (amphetamines, cocaine) had an increased risk of severe maternal morbidity (18-34 years: aOR: 1.92; 95 % CI: 1.80,2.0, >34 years: aOR: 1.85; 95 % CI: 1.66,2.06). Cannabis use disorders were not associated with an increased risk of severe maternal morbidity. CONCLUSION: Substance use disorders during pregnancy, particularly opioids, amphetamines, and cocaine use disorders, may contribute to severe maternal morbidity in the United States.
BACKGROUND: The contribution of substance use disorders to the burden of severe maternal morbidity in the United States is poorly understood. The objective was to estimate the independent association between substance use disorders during pregnancy and risk of severe maternal morbidity. METHODS: Retrospective analysis of a weighted 53.4 million delivery hospitalizations from 2003 to 2016 among females aged>18 in the National Inpatient Sample. We constructed measures of substance use disorders using diagnostic codes for cannabis, opioids, and stimulants (amphetamines or cocaine) abuse or dependence during pregnancy. The outcome was the presence of any of the 21 CDC indicators of severe maternal morbidity. Using weighted multivariable logistic regression, we estimated the association between substance use disorders and adjusted risk of severe maternal morbidity. Because older age at delivery is predictive of severe maternal morbidity, we tested for effect modification between substance use and maternal age by age group (18-34 y vs >34 y). RESULTS: Pregnant women with an opioid use disorder had an increased risk of severe maternal morbidity compared with women without an opioid use disorder (18-34 years: aOR: 1.51; 95 % CI: 1.41,1.61, >34 years: aOR: 1.17; 95 % CI: 1.00,1.38). Compared with their counterparts without stimulant use disorders, pregnant women with a simulant use disorder (amphetamines, cocaine) had an increased risk of severe maternal morbidity (18-34 years: aOR: 1.92; 95 % CI: 1.80,2.0, >34 years: aOR: 1.85; 95 % CI: 1.66,2.06). Cannabis use disorders were not associated with an increased risk of severe maternal morbidity. CONCLUSION: Substance use disorders during pregnancy, particularly opioids, amphetamines, and cocaine use disorders, may contribute to severe maternal morbidity in the United States.
Authors: Elena V Kuklina; Maura K Whiteman; Susan D Hillis; Denise J Jamieson; Susan F Meikle; Samuel F Posner; Polly A Marchbanks Journal: Matern Child Health J Date: 2007-08-10
Authors: Hendrée E Jones; Gabriele Fischer; Sarah H Heil; Karol Kaltenbach; Peter R Martin; Mara G Coyle; Peter Selby; Susan M Stine; Kevin E O'Grady; Amelia M Arria Journal: Addiction Date: 2012-11 Impact factor: 6.526
Authors: Kaitlin M McGrew; Juell B Homco; Tabitha Garwe; Hanh Dung Dao; Mary B Williams; Douglas A Drevets; S Reza Jafarzadeh; Yan Daniel Zhao; Hélène Carabin Journal: Drug Alcohol Depend Date: 2019-12-23 Impact factor: 4.852
Authors: Sarah C Haight; Jean Y Ko; Van T Tong; Michele K Bohm; William M Callaghan Journal: MMWR Morb Mortal Wkly Rep Date: 2018-08-10 Impact factor: 17.586
Authors: Caitlin E Martin; Joseph M Dzierzewski; Lori Keyser-Marcus; Emily K Donovan; Tatiana Ramey; Dace S Svikis; F Gerard Moeller Journal: Front Psychiatry Date: 2022-05-26 Impact factor: 5.435
Authors: Natasia S Courchesne; Laramie R Smith; María Luisa Zúñiga; Christina D Chambers; Mark B Reed; Jerasimos Ballas; Carla B Marienfeld Journal: Alcohol Clin Exp Res Date: 2021-09-19 Impact factor: 3.455